Thanks to the work of NEI scientists and grantees, we’re constantly learning new information about the causes and treatment of vision disorders. Get the latest updates about their work — along with other news about NEI.
Retinitis pigmentosa (RP) is a common hereditary eye disorder that leads to the gradual deterioration of rod cells causing reduced peripheral vision and night vision. Subsequent loss of cone photoreceptors cause the loss of high-resolution daylight...
Scientists funded by the National Eye Institute (NEI) report a novel gene therapy that halts vision loss in a canine model of a blinding condition called autosomal dominant retinitis pigmentosa (adRP).
During Low Vision Awareness Month, the National Eye Institute (NEI), part of the National Institutes of Health, is highlighting new technologies and tools in the works to help the 4.1 million Americans living with low vision or blindness.
NEI-funded researchers at Columbia University Medical Center have shown that vision loss associated with a form of retinitis pigmentosa can be slowed dramatically by reprogramming the metabolism of photoreceptors, or light sensors, in the retina.
Columbia University Medical Center (CUMC) and University of Iowa scientists have used a new gene-editing technology called CRISPR to repair a genetic mutation responsible for retinitis pigmentosa (RP), an inherited condition
A new technique that has the potential to treat inherited diseases by removing genetic defects has been shown for the first time to hinder retinitis pigmentosa, a degenerative eye disease with no known cure that can lead to blindness.